Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin

Cell Cycle

Volumn 12, Issue 21, 2013, Pages 3390-3404

  Corominas Faja, Bruna ^a,b   Oliveras Ferraros, Cristina ^a,b   Cuyàs, Elisabet ^a,b   Segura Carretero, Antonio ^c   Joven, Jorge ^d   Martin Castillo, Begoña ^a,b   Barrajón Catalán, Enrique ^e,f   Micol, Vicente ^e,f   Bosch Barrera, Joaquim ^a,b   Menendez, Javier A ^b,c  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^e MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^f MONTELOEDER S L   (Spain)

Author keywords

ALDEFLUOR ; Cancer stem cells; EGFR; Erlotinib; Lung cancer; Silibinin

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A3; ALPHA CRYSTALLIN; ALPHA TUBULIN; ANKYRIN; BETA TUBULIN; C MYC BINDING PROTEIN; CALCIUM BINDING PROTEIN 7; CATHEPSIN X; CELL CYCLE PROTEIN 6; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; LEUPAXIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN; RIBONUCLEOTIDE REDUCTASE M2 POLYPEPTIDE; RIBOSEPHOSPHATE PYROPHOSPHOKINASE 1 LIKE; RING FINGER PROTEIN 150; RING FINGER PROTEIN 19; SILIBININ; STANNIOCALCIN 2; STEFIN A; THIOREDOXIN INTERACTING PROTEIN; THYROID HORMONE RECEPTOR INTERACTOR 13; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CELL POPULATION; DNA REPLICATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; UNINDEXED SEQUENCE;

ALDEFLUOR; CANCER STEM CELLS; EGFR; ERLOTINIB; LUNG CANCER; SILIBININ;

ALDEHYDE OXIDOREDUCTASES; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SILYMARIN; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84887958940     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26417     Document Type: Article

References (74)

1. Passaro A, Cortesi E, De Marinis F. Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? Expert Rev Anticancer Ther 2011;11:1587-97; PMID:21999132; http://dx.doi.org/10.1586/ era.11.120
2. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29:1059-66; PMID:21282542; http://dx.doi.org/10.1200/JCO.2010.28.5981
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005;353:123-32; PMID:16014882; http://dx.doi.org/10.1056/NEJMoa050753
4. Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012;13:300-8; PMID:22277837; http://dx.doi.org/10.1016/S1470-2045 (11) 70385-0
5. Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin 2012;28:643-50; PMID:22414178; http://dx.doi.org/10.1185/03007995.2012.675880
6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-67; PMID:19692684; http://dx.doi.org/10.1056/NEJMoa0904554
7. Rosell R, Moran T, Cardenal F, Porta R, Viteri S, Molina MA, Benlloch S, Taron M. Predictive biomarkers in the management of EGFR mutant lung cancer. Ann N Y Acad Sci 2010;1210:45-52; PMID:20973798; http://dx.doi.org/10.1111/j.1749- 6632.2010.05775.x
8. Rosell R, Morán T, Carcereny E, Quiroga V, Molina MA, Costa C, Benlloch S, Tarón M. Non-smallcell lung cancer harbouring mutations in the EGFR kinase domain. Clin Transl Oncol 2010;12:75-80; PMID:20156777; http://dx.doi.org/10.1007/S12094-010-0473-0
9. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46; PMID:22285168; http://dx.doi.org/10.1016/S1470-2045 (11) 70393-X
10. Santarpia M, De Pas TM, Altavilla G, Spaggiari L, Rosell R. Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients. Future Oncol 2013;9:327-45; PMID:23469969; http://dx.doi.org/10.2217/fon. 13.6
11. Morgillo F, Bareschino MA, Bianco R, Tortora G, Ciardiello F. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007;75:788-99; PMID:17608727; http://dx.doi.org/10.1111/j.1432- 0436.2007.00200.x
12. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10:281-9; PMID:19632948; http://dx.doi.org/10.3816/CLC.2009.n. 039
13. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31; PMID:19680293; http://dx.doi.org/10.1038/onc. 2009.198
14. Xu Y, Liu H, Chen J, Zhou Q. Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib. Cancer Biol Ther 2010;9:572-82; PMID:20404520; http://dx.doi.org/10.4161/cbt.9.8.11881
15. Ayoola A, Barochia A, Belani K, Belani CP. Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest 2012;30:433-46; PMID:22571344; http://dx.doi.org/10.3109/07357907.2012.666691
16. Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract 2012;2012:817297; PMID:22970367; http://dx.doi.org/10.1155/2012/817297
17. Nakata A, Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets 2012;16:771-81; PMID:22762482; http://dx.doi.org/10.1517/14728222.2012.697155
18. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75ra26; PMID:21430269; http://dx.doi.org/10.1126/ scitranslmed.3002003
19. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62; PMID:16230409; http://dx.doi.org/10.1158/0008-5472. CAN-05-1058
20. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, Lanuti M, Tanabe KK. Epithelial-tomesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 2008;68:2391-9; PMID:18381447; http://dx.doi.org/10.1158/0008- 5472. CAN-07-2460
21. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-98; PMID:16361555; http://dx.doi.org/10.1158/1078-0432. CCR-05-1492
22. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006;4:521-8; PMID:16877703; http://dx.doi.org/10.1158/ 1541-7786. MCR-06-0095
23. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2 011; 6:1152-61; PMID:21597390; http://dx.doi.org/10. 1097/JTO.0b013e318216ee52
24. Chung JH, Rho JK, Xu X, Lee JS, Yoon HI, Lee CT, Choi YJ, Kim HR, Kim CH, Lee JC. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011;73:176-82; PMID:21168239; http://dx.doi.org/10.1016/j.lungcan. 2010.11.011
25. Chang TH, Tsai MF, Su KY, Wu SG, Huang CP, Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, et al. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am J Respir Crit Care Med 2011;183:1071-9; PMID:21037017; http://dx.doi.org/10.1164/rccm.201009-1440OC
26. Bryant JL, Britson J, Balko JM, Willian M, Timmons R, Frolov A, Black EP. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 2012;106:148-56; PMID:22045191; http://dx.doi.org/10.1038/bjc.2011.465
27. Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 2013;8:e57692; PMID:23520479; http://dx.doi.org/10.1371/journal.pone.0057692
28. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60; PMID:22751098; http://dx.doi.org/10.1038/ng.2330
29. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19:279-90; PM ID:23091115; http://dx.doi.org/10.1158/1078-0432. CCR-12-1558
30. Ouyang G, Wang Z, Fang X, Liu J, Yang CJ. Molecular signaling of the epithelial to mesenchymal transition in generating and maintaining cancer stem cells. Cell Mol Life Sci 2010;67:2605-18; PMID:20238234; http://dx.doi.org/10. 1007/s00018-010-0338-2
31. Singh A, Settleman J. EMT, ca ncer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010;29:4741-51; PMID:20531305; http://dx.doi.org/10.1038/onc.2010.215
32. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 2010;13:109-18; PMID:20692200; http://dx.doi.org/10.1016/j.drup. 2010.07.001
33. Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 2011;13:211; PMID:21672282; http://dx.doi.org/10.1186/bcr2876
34. Floor S, Van Staveren WC, Larsimont D, Dumont JE, Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011;30:4609-21; PMID:21643013; http://dx.doi.org/10.1038/onc.2011.184
35. Nurwidya F, Takahashi F, Murakami A, Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 2012;44:151-6; PMID:23091440; http://dx.doi.org/10.4143/crt.2012.44.3.151
36. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 2012;22:396-403; PMID:22554795; http://dx.doi.org/10.1016/j.semcancer.2012.04.001
37. Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta 2012;1826:272-96; PMID:22579961
38. Dave B, Mittal V, Tan NM, Chang JC. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 2012;14:202; PMID:22264257; http://dx.doi.org/10.1186/bcr2938
39. Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to- mesenchymal transition in lung carcinogenesis. Respirology 2012;17:1048-59; PMID:22452538; http://dx.doi.org/10.1111/j.1440-1843.2012.02173.x
40. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011;32:1299-304; PMID:21665887; http://dx.doi.org/10.1093/ carcin/bgr110
41. Qiu X, Wang Z, Li Y, Miao Y, Ren Y, Luan Y. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett 2012;323:161-70; PMID:22521544; http://dx.doi.org/ 10.1016/j.canlet.2012.04.004
42. Salcido CD, Larochelle A, Taylor BJ, Dunbar CE, Varticovski L. Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer 2010;102:1636-44; PMID:20424609; http://dx.doi.org/10.1038/sj.bjc.6605668
43. Kubo T, Takigawa N, Osawa M, Harada D, Ninomiya T, Ochi N, Ichihara E, Yamane H, Tanimoto M, Kiura K. Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Sci 2013;104:78-84; PMID:23066953; http://dx.doi.org/10.1111/cas.12045
44. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One 2013;8:e57020; PMID:23469181; http://dx.doi.org/10.1371/journal.pone.0057020
45. Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, Sun X, Chen D, Yin R, Zhu H, et al. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis 2013;4:e633; PMID:23681228; http://dx.doi.org/10. 1038/cddis.2013.152
46. Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Torres-Garcia VZ, Corominas-Faja B, Cuyàs E, Bonavia R, Visa J, Martin-Castillo B, Barrajón-Catalán E, et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinibsensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 2013;3:2560; PMID:23994953; http://dx.doi.org/10.1038/srep02560
47. Cufí S, Bonavia R, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Cuyàs E, Martin-Castillo B, Barrajón- Catalán E, Visa J, Segura-Carretero A, et al. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep 2013;3:2459; PMID:23963283; http://dx.doi.org/10. 1038/srep02459
48. Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, Kim HR, Kim CH, Choi CM, Lee JC. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther 2010;9:3233-43; PMID:21159609; http://dx.doi.org/10. 1158/1535-7163. MCT-10-0625
49. Mateen S, Raina K, Agarwal C, Chan D, Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J Pharmacol Exp Ther 2013;345:206-14; PMID:23461975; http://dx.doi.org/10.1124/jpet.113.203471
50. Mateen S, Raina K, Agarwal R. Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer. Nutr Cancer 2013;65(Suppl 1):3-11; PMID:23682778; http://dx.doi.org/10.1080/01635581.2013. 785004
51. Sadava D, Kane SE. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett 2013;339:102-6; PMID:23879966; http://dx.doi.org/10.1016/j.canlet.2013.07.017
52. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H, Ito H. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication. Lung Cancer 2009;65:223-9; PMID:19144445; http://dx.doi.org/10.1016/j.lungcan. 2008.11.007
53. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, et al. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in nonsmall cell lung cancer. Lung Cancer 2011;72:229-37; PMID:20884074; http://dx.doi.org/10.1016/j.lungcan. 2010.08.020
54. Toyokawa G, Masuda K, Daigo Y, Cho HS, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Chino M, Field HI, et al. Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer 2011;10:65; PMID:21619671; http://dx.doi.org/10.1186/1476-4598-10-65
55. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, Wada H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 2007;13:6938-46; PMID:18056168; http://dx.doi.org/10.1158/1078-0432. CCR-07-1539
56. Chong JL, Wenzel PL, Sáenz-Robles MT, Nair V, Ferrey A, Hagan JP, Gomez YM, Sharma N, Chen HZ, Ouseph M, et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009;462:930-4; PMID:20016602; http://dx.doi.org/10.1038/nature08677
57. Park YY, Park ES, Kim SB, Kim SC, Sohn BH, Chu IS, Jeong W, Mills GB, Byers LA, Lee JS. Development and validation of a prognostic geneexpression signature for lung adenocarcinoma. PLoS One 2012;7:e44225; PMID:22970185; http://dx.doi.org/10.1371/journal.pone.0044225
58. Yu YH, Chiou GY, Huang PI, Lo WL, Wang CY, Lu KH, Yu CC, Alterovitz G, Huang WC, Lo JF, et al. Network biology of tumor stem-like cells identified a regulatory role of CBX5 in lung cancer. Sci Rep 2012;2:584; PMID:22900142; http://dx.doi.org/10.1038/srep00584
59. Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, Serrano M. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 2006;440:702-6; PMID:16572177; http://dx.doi.org/10.1038/nature04585
60. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009;178:48-55; PMID:18952074; http://dx.doi.org/10.1016/j.cbi. 2008.09.029
61. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W. ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells. Mol Cancer 2008;7:87; PMID: 19025616; http://dx.doi.org/ 10.1186/1476-4598-7-87
62. Sullivan J P, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010;70:9937-48; PM ID: 21118965; http://dx.doi.org/10.1158/0008-5472. CAN-10-0881
63. Liang D, Shi Y. Aldehyde dehydrogenase-1 is a specific marker for stem cells in human lung adenocarcinoma. Med Oncol 2012;29:633-9; PMID:21484084; http://dx.doi.org/10.1007/s12032-011-9933-9
64. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, et al. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 2013;328:144-51; PMID:22935675; http://dx.doi.org/10.1016/j.canlet.2012.08.021
65. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006;103:11707-12; PMID:16857736; http://dx.doi.org/10.1073/pnas.0603806103
66. Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL, Liang R, Leung AY. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007;21:1423-30; PMID:17476279; http://dx.doi.org/10.1038/ sj.leu.2404721
67. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005;23:752-60; PMID:15917471; http://dx.doi.org/10.1634/stemcells.2004-0292
68. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer 2008;59:340-9; PMID:17920722; http://dx.doi.org/10.1016/j.lungcan. 2007.08.033
69. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009;7:330-8; PMID:19276181; http://dx.doi.org/10.1158/1541-7786. MCR-08-0393
70. Marcato P, Dean CA, Giacomantonio CA, Lee PW. Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle 2011;10:1378-84; PMID:21552008; http://dx.doi.org/10.4161/cc.10.9.15486
71. Shien K, Toyooka S, Yamamoto H, Soh J, Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 2013;73:3051-61; PMID:23542356; http://dx.doi.org/10.1158/0008-5472. CAN-12-4136
72. Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 2012;113:1733-43; PMID:22213051
73. Cufí S, Bonavia R, Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Martin-Castillo B, Barrajón- Catalán E, Visa J, Segura-Carretero A, et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol 2013;60:360-8; PMID:23916468; http://dx.doi.org/10.1016/j.fct.2013.07.063
74. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70; PMID:12756227; http://dx.doi.org/10.1101/gad.1061803